| Biological Information | |
|---|---|
| Background Information: | Troglitazone is a selective agonist of the peroxisome proliferator-activated receptor-γ (PPARγ, EC50=555nM) with no activity for PPARα or PPARδ. Troglitazone is a synthetic antidiabetic and anti-inflammatory drug previously prescribed to patients with type 2 diabetes mellitus, but was withdrawn from the market in 2000 due to toxicity issues. Provided as 5 mg of dry powder. |
| Target Name: | Troglitazone |
| Usage | |
| Product Type: | Control Ligands & Inhibitors |
| Application: | Drug Discovery & Development |
| Storage Conditions: | Store at ≤-20°C. Please avoid multiple freeze/thaw cycles. |
| Usage Disclaimer: | These products may be covered by issued US and/or foreign patents, patent application and subject to Limited Use Label License. Please visit discoverx.com/license for a list of products that are governed by limited use label license terms and relevant patent and trademark information. |
| Additional Information | |
| Brand: | DiscoverX |
Troglitazone
Troglitazone is an agonist for PPARγ. This product is provided as 5 mg of dry powder.
Datasheets
92-1138 Datasheet
View Document